Moderna
Search results
Drug Classes. Our goal is clear: we want to provide better medicines for patients worldwide. Our toolbox includes a broad range of drug classes and platform technologies including mRNA-based therapies, cell therapies, small molecules as well as antibodies and other protein-based therapies.
- Our Senior Team
Prof. Pedro L. Alonso, M.D., Ph.D., joined BioNTech in 2023...
- Open Positions
BioNTech SE An der Goldgrube 12 55131 Mainz, Germany. T: +49...
- Vision & Mission
With decades of deep immunology expertise and experience in...
- Newsroom
Here you can find all media data in an overview for...
- Therapeutic Areas
We aspire to find new and better ways to treat and prevent...
- Manufacturing
As part of these plans, BioNTech is collaborating with the...
- Our Senior Team
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [12] and Christoph Huber, [13] with a seed investment of €150 million from MIG Capital and AT Impf. [14] The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy. [3]
With decades of deep immunology expertise and experience in developing and optimizing mRNA as part of its broad suite of novel technologies, the company is working with the global community to defeat life-threatening and serious diseases such as cancer, COVID-19, malaria and tuberculosis.
BioNTech US is a fully integrated subsidiary with a strong foundation in Europe and a focus on the development of novel neoantigen-targeted T cell therapies, complementing BioNTech’s highly innovative scientific approach and diversified pipeline of transformative cancer medicines.
We aspire to find new and better ways to treat and prevent diseases. We aim to improve standards of care or establish new ones. We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer and infectious diseases.
21 Feb 2021 · Vaksin Pfizer-BioNTech adalah vaksin pertama yang telah memperolehi kelulusan bersyarat daripada Pihak Berkuasa Kawalan Dadah (PBKD) dan NPRA pada 8 Januari 2021 lalu. Sehingga Februari 2021, Malaysia telah mendapat akses bekalan vaksin COVID-19 sebanyak 66.7 juta dos melalui Fasiliti COVAX dan pembelian awal daripada 5 pengeluar vaksin COVID-19.
18 Ogo 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
